Newly diagnosed myeloma study using blood-marker risk groups
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This Phase 2/3 trial tests whether matching treatment choices to a patient’s myeloma risk pattern (using blood and scan results) improves outcomes. It is for people with newly diagnosed, untreated, symptomatic multiple myeloma who may also receive transplant-related treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have newly diagnosed, untreated, symptomatic multiple myeloma (not smoldering), with documented organ or bone involvement
- You have measurable myeloma markers in blood and/or urine (such as M-protein or abnormal free light chains)
- Your myeloma test results fit the study’s required risk category and gene-expression pattern (from the study’s specific testing)
- You are between 18 and 70 years old and can attend study visits and follow the plan
- You are healthy enough for stem-cell collection and high-dose melphalan (your doctor must think this is safe)
- You can follow strict pregnancy prevention rules (especially important if you can become pregnant) and agree to regular pregnancy testing if needed
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests the best combination of medicines for newly diagnosed multiple myeloma patients who are headed to an autologous stem cell transplant (ASCT). It compares extended VRD plus versus Isa-VRD versus Isa-V-Iberdomide to see which approach works best and is tolerable.
This trial tests a combination of four drugs (isatuximab, iberdomide, bortezomib, and dexamethasone) for people newly diagnosed with multiple myeloma who are either unable or choose not to have a stem cell transplant. The goal is to see if this combination can effectively control the disease.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
This Phase 2 trial tests whether adding isatuximab and lenalidomide as long-term treatment after stem cell transplant can help keep high-risk multiple myeloma under control. It may help some people reduce the chance of the disease coming back after transplant.
This trial tests a combination of study drugs as the first treatment for newly diagnosed multiple myeloma, followed by maintenance based on your risk and response. It aims to improve outcomes while allowing some patients to postpone or avoid a stem cell transplant.
This study tests a combination of four medicines (isatuximab, bortezomib, lenalidomide, dexamethasone) for people with newly diagnosed high-risk multiple myeloma who are not having a stem cell transplant. The goal is to see if this combination can better control the disease and improve outcomes.
Hear when a new Newly Diagnosed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.